3B Blackbio Dx enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast close	FY25Mar 2025	FY24Mar 2024


6.2	6.2	6.4
0.3	0.3	0.7
−5.9	−5.9	−5.6

273	273	228
0.1%	0.1%	0.3%
90.5	90.5	70.7
49.9	49.9	35.1
49.0	49.0	34.2
44.5	44.5	28.5
44.5	44.5	28.5

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

3BBLACKBIO₹1,359.20

3B Blackbio Dx Limited

· Pharma & Health

₹ CrorePeersHEALTHX SURAKSHA KRSNAA NEPHROPLUS

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	Current last close
- Cash, Equiv & ST Investments	6.4	6.2	6.2
+ Total Debt	0.7	0.3	0.3
Net Debt (memo)	-5.6	-5.9	-5.9

Total Capital	228.5	273.1	273.1
Total Debt/Total Capital	0.31	0.11	0.11
Reference Items — Trailing FY Values
Sales	70.7	90.5	90.5
EBITDA	35.1	49.9	49.9
EBIT	34.2	49.0	49.0
Operating Cash Flow	28.5	44.5	44.5
Free Cash Flow	28.5	44.5	44.5

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.